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Abstract
Background: Zeolites are crystalline compounds with microporous structures of Si-tetrahedrons. In the gut, these
silicates could act as adsorbents, ion-exchangers, catalysts, detergents or anti-diarrheic agents. This study evaluated
whether zeolite supplementation affects biomarkers of intestinal wall permeability and parameters of oxidation and
inflammation in aerobically trained individuals, and whether it could improve their performance.
Methods: In a randomized, double-blinded, placebo controlled trial, 52 endurance trained men and women,
similar in body fat, non-smokers, 20–50 years, received 1.85 g of zeolite per day for 12 weeks. Stool samples for
determination of intestinal wall integrity biomarkers were collected. From blood, markers of redox biology,
inflammation, and DNA damage were determined at the beginning and the end of the study. In addition,
VO2max and maximum performance were evaluated at baseline and after 12 weeks of treatment. For statistical
analyses a 2-factor ANOVA was used.
Results: At baseline both groups showed slightly increased stool zonulin concentrations above normal. After
12 weeks with zeolite zonulin was significantly (p < 0.05) decreased in the supplemented group. IL-10 increased
tendentially (p < 0.1) in the zeolite group. There were no significant changes observed in the other measured
parameters.
Conclusions: Twelve weeks of zeolite supplementation exerted beneficial effects on intestinal wall integrity as
indicated via decreased concentrations of the tight junction modulator zonulin. This was accompanied by mild
anti-inflammatory effects in this cohort of aerobically trained subjects. Further research is needed to explore
mechanistic explanations for the observations in this study.
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Background
Zeolite is a collective name for minerals and chemical
compounds within the group of silicates. Natural zeo-
lites are crystalline compounds of volcanic origin with
microporous structures of Si- and AI-tetrahedrons
(SiO4, AIO4), linked through the common oxygen
atoms to form an open crystal structure [1]. The ar-
rangement of the atoms affects the water-binding cap-
acities of the microporous structures of the zeolite
minerals, like a “rock-sponge”. The grid structure of
zeolites can act as inorganic cation-exchanger, adsorb-
ent, detergent builder, and active reservoir for metal-
catalyzed reactions [2–6]. These properties have
earned them extensive industrial applications. Zeolite’s
use in medicine, especially micronized natural zeolite-
clinoptilolite, is a relatively novel subject of interest.
Animal studies have demonstrated that natural zeolite-
clinoptilolite exerts immunostimulatory effects, modu-
lates anti- and pro-inflammatory mechanisms, and
postulate its use as an adjuvant in anticancer therapy
[7, 8]. Other researchers describe zeolite’s capability to
adsorb glucose, antidiarrheic effects, and its strong
antioxidant activity [9–11].
Regarding sports nutrition, zeolite’s effects in the gut,
its effects on inflammatory metabolism and antioxidant
activity, and effects on performance are of specific inter-
est. For instance, in performance sports there is a high
prevalence of gastrointestinal complaints among endur-
ance athletes like runners and triathletes [12]. These
problems are attributed to changed blood flow that is
shunted from the viscera to skeletal muscle or the heart
[13]. Symptoms described are nausea, stomach and in-
testinal cramps, vomiting and diarrhea, and are accom-
panied by increased intestinal wall permeability. Such a
“leaky gut” leads to endotoxemia, and results in in-
creased susceptibility to infectious- and autoimmune
diseases, due to absorption of pathogens/toxins into tis-
sue and blood stream [14–16].
For this study, we hypothesized that the above de-
scribed properties of zeolite are able to
– modulate intestinal wall integrity via impact on
zonulin secretion from enterocytes,
– reduce pro-oxidative and pro-inflammatory
processes in the gut via binding of oxidants,
– increase VO2max and maximum performance as
resulting outcomes of an improved gut wall
integrity, redox balance and anti-inflammatory
metabolism.
The effects of zeolites on intestinal barrier integrity,
inflammation, redox biology, as well as on physical per-
formance are not elucidated. From these perspectives,
nutritional solutions like zeolite supplementation could
be of reasonable relevance for athlete’s health and
performance.
Hence, we focused the primary outcome of this study
to explore the effects of a zeolite-clinoptilolite supple-
ment on markers of intestinal barrier integrity in trained
men and women. The secondary outcome of this trial
was to evaluate whether the zeolite supplementation af-
fects blood markers of redox biology and inflammation.
A third hypothesis tested whether the zeolite supple-
mentation could affect VO2max and maximum perform-
ance in a step test ergometry.
Methods
Subjects
Fifty two endurance trained subjects, most of them cyclists
and triathletes, participated in this trial. Inclusion criteria:
healthy males or females, 25 – 50 years, aerobically trained
(VO2max from 45 mL/kg
. min-1 to 65 mL/kg . min-1), non-
smokers, no dietary or nutritional supplement use
within four weeks prior to the first blood drawing/stool
collection. Exclusion criteria: smokers, subjects outside
the predefined VO2max range, subjects who underwent
major changes in training regimens during the study,
chronic or excessive alcohol consumption, recent sur-
gery or illness, body fat > 20 %. Body fat content and
distribution was estimated by a computerized optical
device Lipometer (Möller Messtechnik, Graz, Austria),
as described by Möller, et al [17]. Besides inclusion and
exclusion criteria, a standard blood chemistry panel
was determined and all subjects completed a medical
history.
Ethical aspects, recruitment and randomization
All subjects provided written informed consent prior to
participating in this investigation. This study was con-
ducted according to the guidelines of the Declaration of
Helsinki for Research on Human Subjects 1989 and was
approved by the Ethical Review Committee of the Med-
ical University of Graz, Austria. The trial was registered
under www.clinicaltrials.gov, identifier: NCT01831492.
The study focused trained men and women and was
announced in the largest sport magazine of Austria.
After a telephone screening conducted by the research
team, 61 subjects volunteered for eligibility testing. From
those, 56 men and women were selected and entered the
study program.
Before randomization VO2max tests were conducted
and VO2max data were ranked from highest to lowest.
Subjects were randomized into blocks of four and se-
quentially numbered. To guarantee a balanced VO2max
distribution between groups (zeolite versus placebo) we
conducted stratification via VO2max rank statistics.
Randomization code was held by a third party (Union of
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Sport and Exercise Scientists Austria) and handed over
for statistical analyses after collection of all data.
Study design and time schedule
This was a randomized, placebo controlled, double-
blinded study. All eligibility testing - such as blood
panel, eligibility for exercise, clinic check-up, medical
history questionnaire, one-on-one interview - was final-
ized prior to the 1st VO2max testing. On the day of the
1st VO2max testing blood and stool samples were col-
lected before the subjects conducted the cycle step test
ergometries (= first visit and 1st VO2max testing) to ex-
haustion. After completion of these 56 ergometer step
tests, the investigators dispensed the randomized capsule
supply according to the subject’s VO2max-ranking. After
12 weeks taking the capsules as instructed, subjects
returned to the study side for the second blood and stool
collection and another VO2max testing, and returned
their remaining capsules to adjust compliance.
Dietary assessment
Subjects were instructed to maintain their habitual diet,
lifestyle and training regimen during the 12 weeks study
and to duplicate their diet before each blood/stool col-
lection. Before the first visit at the study site, subjects
completed a 7-day food record for nutrient intake
assessment. They subsequently received copies of their
7-day diet records and were instructed to replicate the
diet prior to the second visit. Diet records were analyzed
for total calories, protein, carbohydrate, fat, cholesterol,
fiber, water, alcohol, several vitamins, minerals, and fatty
acids using “opti diet” software 5.0 (GOEmbH, Linden,
Germany).
Treatment
The subjects randomized to zeolite-clinoptilolite (n = 28)
received boxes with capsules containing (per capsule):
Zeolite 307,50 mg, Dolomite 75,17 mg (thereof Magne-
sium 15,79 mg; Calcium 34,9 mg), Maca 27,33 mg,
Cellulose 90 mg (PANACEO SPORT®, Panaceo Inter-
national Active Mineral Production GmbH, Villach,
Austria). The placebo consisted of identical appearing
capsules with 500 mg Cellulose per capsule. All subjects
were instructed to take 6 capsules per day, 3 capsules in
the morning with breakfast and the other 3 capsules
with the last meal of the day throughout 12 weeks. To
ensure good compliance, subjects were called and e-
mailed biweekly to remind and motivate them to adhere
to the suggested instructions.
VO2max and performance tests
To assess the supplement’s impact on VO2max and max-
imum performance in watt (W), and to avoid biased re-
sponses caused by differences in aerobic fitness levels,
we conducted step wise incremental ergometries until
exhaustion to evaluate VO2max and maximum perform-
ance of each subject, at the beginning and the end of the
study. Exhaustion was reached/defined when cadence
could not be maintained with maximum exertion on the
last (heaviest) step. They were instructed not to perform
physical training 3 days prior to the exercise test. All
subjects performed an incremental cycle ergometer exer-
cise test (EC 3000, Custo med GmbH, Ottobrunn,
Germany) at 80 rpm. After a three minute rest phase sit-
ting inactive on the ergometer, work rate started at
60 W (women 40 W) for three minutes and was increased
15 W every minute until voluntary exhaustion. A standard
electrocardiogram was recorded during the entire test,
which was supervised by a physician. Respiratory gas
exchange variables were measured throughout the
incremental exercise tests using a breath-by-breath mode
(Metalyzer 3B, Cortex Biophysik GmbH, Leipzig,
Germany). During these tests, subjects breathed through a
facemask. Oxygen uptake (VO2), carbon dioxide output
(VCO2), minute ventilation (VE), breathing rate (BR) and
tidal volume (VT) were continuously obtained. Blood
pressure as well as heart rate (HR) were monitored
throughout the tests using a commercially available heart
rate monitor (Polar Vantage NV, Polar Electro Finland).
Feces and blood collection
For the measurements of zonulin and alpha1-antitrypsin
from feces the subjects collected samples at baseline and
after 12 weeks. They used standardized stool tubules
and brought the samples with a cooling bag, within 24 h
after collection, to the laboratory. All samples were ana-
lyzed within 48 h after dispensing. Throughout the
12 weeks treatment the subjects recorded a stool proto-
col to monitor stool appearance with help of the Bristol
stool scale/chart [18].
Blood collections were conducted in supine position
from a medial cubital vein at baseline and after 12 weeks
of treatment. Venous blood was collected to determine
carbonyl proteins (CP), 8-iso-prostaglandin F2α (8-iso-
PGF2α), plasma glutathione peroxidase (GPx3), uric acid,
vitamin C, DNA strand-breaks, cytokines like tumor ne-
crose factor alpha (TNF-α), interleukines 6, 8, 10, 22
(IL-6, IL-8, IL-10, IL-22). For determination of a blood
clinical chemistry panel we measured Mg, Ca, Fe, K, Na,
AI, P, Cl, ferritin, transferrin, liver and kidney parameters
(ALT, AST, GGT, creatinine), testosterone, sex hormone
binding globulin (SHBG), free androgen index (FAI), and
a hemogram.
Stool analyses
Zonulin and α1-antitrypsin were analyzed with com-
mercially available ELISA kits (Immundiagnostik AG,
Bensheim, Germany).
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Analyses of blood parameters
The quantity of carbonyls in protein samples (carbonyl
proteins, CP) was analyzed with a commercially avail-
able ELISA kit from Immundiagnostik AG, Bensheim,
Germany.
An isotope diluted liquid chromatography tandem
mass spectrometry (LC-MS) approach was used for the
detection of 8-iso-PGF2α.
For analyses of plasma GPx3, the Human Glutathione
Peroxidase ELISA Kit assay was used (Cusabio,
antibodies-online GmbH, Aachen, Germany).
For DNA strand-break analyses in mononuclear cells
the Comet assay was used.
For analyses of cytokines IL-6, IL-8, IL-10 and IL-22,
an ELISA kit was used (Cusabio; antibodies-online
GmbH; Aachen, Germany).
For quantitative determination of TNF-alpha an
enzyme-linked-immunosorbent Assay (TNF-alpha ELISA;
Immundiagnostik AG, Bensheim, Germany) was used.
For analyses of vitamin C, uric acid, minerals, func-
tional liver and kidney markers, as well as androgens,
fully automated routine clinical chemistry analyzers were
used (vitamin C: LaChrom L7200, Merck KG, Darmstadt,
Germany; all the others: CI 8200, Abbott Diagnostics,
Green Oaks, IL).
The hemogram was measured with the ABX Micros
60 (AxonLab, Baden, Switzerland) from EDTA-blood.
Statistical analyses and sample size calculation
Per protocol analyses were performed using SPSS for
Windows software, version 19.0. Data are presented as
mean ± SD. Statistical significance was set at P < 0.05.
The Shapiro-Wilk test was used to determine normal
distribution. Baseline characteristics, nutrient and clin-
ical chemistry data, were compared by unpaired
Student’s t-test. Data obtained for zonulin and α1-
antitrypsin from feces, as well as CP, 8-iso-PGF2α, GPx3,
uric acid, vitamin C, DNA strand-breaks, IL-6, IL-8, IL-
10, IL-22 from blood and performance data were ana-
lyzed using a univariate, two-factorial, repeated measures
analysis of variance (ANOVA). Factors: treatment (zeo-
lite supplementation versus placebo), time (baseline ver-
sus 12 weeks of treatment). Significant interactions and
main effects were post-hoc analyzed by using Bonferroni
correction. Performance data were analyzed separately
for men and women.
Sample size calculation was based on zonulin, redox
markers and cytokines. We estimated 12 (zonulin) - 25
(TNF-α) subjects per group (1 : 1 distribution) - depend-
ing on the calculated parameter, standard deviation and
effect size - to reach a probability of error (alpha/2) of
5 % (α = 0.05) and 80 % power. TNF-α sample size calcu-
lation resulted in the highest number of all parameters:
50 subjects. Hence, and including a drop-out rate of
10 %, 56 subjects were recruited.
Results
Study population, baseline characteristics, nutrition
A CONSORT diagram outlining participant recruitment
is depicted Fig. 1. Of the 56 randomized subjects, 52
completed the full program and entered statistical ana-
lyses (9 women, 43 men). Two men terminated earlier
due to injuries unrelated to the study, one men became
sick with influenza, and one woman did not adhere to
the strict exclusion of any supplement use.
Returned capsule count after the treatment period re-
vealed a compliance >90 % in both groups. Groups did
not differ in age, gender, BMI, VO2max, body weight and
fat, clinical blood chemistry variables, and diet (P > 0.05).
Subjects characteristics are presented in Table 1.
Markers of intestinal barrier permeability
Zonulin was determined from feces from the last stool
prior to the visit at the study site. There were no signifi-
cant differences between groups at baseline (P > 0.1) but
the mean values of both groups were slightly above cut-
off (ref. range: < 55 ng . mL-1, see Fig. 2). After 12 weeks
with zeolite zonulin decreased in the verum group into
normal physiological range (43.8 ± 14.3 ng . mL-1)
whereas the placebo group did not really change over
time (59.6 ± 12.3 ng . mL-1). This revealed a significant
difference between groups/treatments (P = 0.006) and is
corresponding to a decrease of almost 30 % in the zeo-
lite supplemented group (Table 2).
Alpha1-antitrypsin: There were no differences between
groups at any time point assessed (P > 0.1). Mean con-
centrations in feces were within normal range at baseline
and after 12 weeks of treatment (<37.5 mg . dL-1,
Table 2).
Redox markers
CP: There were no differences in CP concentrations be-
tween groups, neither at baseline nor after 12 weeks of
treatment (P > 0.1). There was a significant effect of time
(P < 0.001) to increased values in both groups at the end
of the study. Whereas CP mean concentrations were
only slightly above cut-off (200 pmol . mg-1) at baseline,
the concentrations were around 500 pmol . mg-1 after
12 weeks (Table 2).
8-iso-PGF2α did not show differences between groups
at any time point assessed (P > 0.1). 8-iso-PGF2α mean
concentrations were within normal range at baseline
and after 12 weeks of treatment (50 - 400 pg . mL-1,
Table 2).
Plasma GPx3 activities did not differ between groups
at any time point assessed (P > 0.1). There was a signifi-
cant effect of time (P < 0.001) to increased values at the
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end of the study. Whereas GPx3 mean values were only
slightly above cut-off (98 IU . L-1) at baseline, the con-
centrations were close to 200 IU . L-1 after 12 weeks
(Table 2).
DNA strand-breaks did not show differences between
groups at any time point assessed (P > 0.1). All values
were within normal range at baseline and after 12 weeks
of treatment (0 – 70 AU, Table 2).
Vitamin C and uric acid did not show differences be-
tween groups, neither at baseline (Table 1) nor after
12 weeks of treatment (P > 0.1, data not shown). All
values were within normal ranges at both time points
assessed.
Markers of inflammation
TNF-alpha concentrations did not differ between groups
at both time points assessed (P > 0.1). There was a sig-
nificant effect of time (P = 0.024) to increased values in
both groups at the end of the study. All values were
within normal range at baseline and after 12 weeks of
treatment (0 – 69 pg . mL-1, Table 2).
The pro-inflammatory cytokines IL-6, IL-8 and IL-
22 did not show differences between groups at any
time point assessed (P > 0.1). All these cytokines con-
centrations were either within normal ranges at base-
line and after 12 weeks of treatment or unobtrusive
(Table 2).
n = 127
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Fig. 1 CONSORT diagram
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Table 1 Group characteristics, performance data, clinical chemistry and nutrition data of 52 trained subjectsa, estimated at baseline
Variable Reference rangeb,c Zeolite Placebo
(n = 27) (n = 25)
Group characteristics, VO2max, Pmax data:
Age, yr 33.6 ± 5.3 37.2 ± 4.9
BMI, kg . m-2 22.7 ± 2.2 23.2 ± 2.1
Weight, kg (men) 73.8 ± 5.9 74.6 ± 6.3
Weight, kg (women) 56.7 ± 3.9 58.8 ± 3.4
Total body fat, % (men) 13.5 ± 3.1 14.1 ± 3.9
Total body fat, % (women) 17.7 ± 2.1 17.3 ± 2.2
VO2max, mL (men)
d 4263 ± 132 4187 ± 119
relVO2max, mL
. kg-1 . min-1(men)e 53.2 ± 5.1 52.3 ± 4.6
VO2max, mL (female)
f 2367 ± 128 2357 ± 132
relVO2max, mL
. kg-1 . min-1(women)g 42.5 ± 3.6 41.4 ± 3.6
Pmax, W (men)
h 360.4 ± 29.1 352.3 ± 24.6
relPmax, W
. min-1 (men)i 4.6 ± 0.5 4.5 ± 0.4
Pmax, W (women)
j 240.5 ± 25.5 241.8 ± 23.6
relPmax, W
. min-1 (women)k 4.2 ± 0.8 4.1 ± 0.7
Clinical Chemistry (exerpts):
Glucose, mmol . L-1 3.9 - 6.1 4.1 ± 0.5 4.6 ± 0.4
Hemoglobin, g . L-1 136 - 172 152 ± 12 150 ± 19
Iron, μmol . L-1 11 - 32 21.4 ± 5.5 20.6 ± 4.9
Ferritin, μg . L-1 18 - 300 111 ± 32 99 ± 26
Cholesterol, mmol . L-1 <5.85 4.27 ± 1.03 4.36 ± 1.13
HDL, mmol . L-1 0.80 - 1.80 1.20 ± 0.13 1.23 ± 0.19
Triglycerides, mmol . L-1 <1.80 0.92 ± 0.32 0.98 ± 0.26
Testosterone, nmol . L-1(men) 10 - 31 16.3 ± 4.9 18.2 ± 4.1
Creatinine, μmol . L-1 50 - 110 90 ± 11 89 ± 17
Vitamin C (ascorbate), μmol . L-1 30 - 110 57.3 ± 15.7 63.6 ± 22.9
Uric acid, μmol . L-1 120 - 420 315.5 ± 69.6 311.4 ± 64.4
Aluminium, nmol . L-1 0 - 560 199.2 ± 43.6 209.1 ± 59.3
Nutrition (exerpts):
Energy, kJ . d-1 11776 - 13902 12445 ± 893 12756 ± 1455
Fat, % <30 % of kJ · d-1 33.5 ± 4.2 % 34.1 ± 3.1 %
Protein, % 10 - 15 % of kJ · d-1 16.3 ± 2.1 % 15.8 ± 3.2 %
Carbohydrates, % >50 % of kJ · d-1 48.3 ± 9.1 % 49.2 ± 10.3 %
Water, mL 2600 2998 ± 495 2779 ± 682
Fibres, g 30 26 ± 5 25 ± 4
Vitamin C, mg 72 - 106 132 ± 48 118 ± 67
Vitamin E, mg 14 15 ± 5 13 ± 9
Folate, μg 434 - 505 282 ± 155 292 ± 165
Vitamin B-6, mg 3.2 - 3.8 1.89 ± 2.9 1.85 ± 2.8
Vitamin B-12, μg 3.3 – 3.7 5.0 ± 2.8 5.6 ± 1.4
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Anti-inflammatory IL-10: There were no significant
differences between groups at baseline (P > 0.1). After
12 weeks with zeolite IL-10 increased in the zeolite
group whereas the placebo group did not really change
over time. This revealed a tendential difference between
groups/treatments (P = 0.087, Table 2) at the end of the
study.
Performance data
VO2max and Pmax did not differ between treatment groups
at any time point assessed (P > 0.1), neither in men nor in
women. Also the factor time (baseline – 12 weeks) had no
influence on these parameters (P > 0.1).
Other blood analytes
Blood minerals (including aluminum), liver and kidney
parameters, androgen status, and hemogram did not
show differences between groups, neither at baseline
(excerpts see Table 1) nor after 12 weeks of treatment
(P > 0.1, data not shown). All values were within normal
ranges at both time points assessed.
Discussion
This study evaluated whether zeolite supplementation
could influence biomarkers of gut wall and tight junc-
tion integrity, oxidation and inflammation in aerobically
trained individuals.
Markers of intestinal barrier permeability
Tight junctions are protein structures that represent the
major barrier within the intestinal paracellular pathway
and are therefore key factors of intestinal permeability.
They regulate the movement of fluid, macromolecules
and leukocytes between the bloodstream and the intes-
tinal lumen, and vice versa [19].
Zonulin - a protein of the haptoglobin family - is de-
scribed as the main physiological modulator of intercel-
lular tight junctions. Increased zonulin concentrations
are related to changes in tight junction competency and
Table 1 Group characteristics, performance data, clinical chemistry and nutrition data of 52 trained subjectsa, estimated at baseline
(Continued)
Sodium, mg >646 2711 ± 885 2689 ± 970
Potassium, mg 2171 - 2523 3362 ± 904 3436 ± 1251
Magnesium, mg 185 - 361 408 ± 134 385 ± 119
Calcium, mg 1085 - 1261 1080 ± 395 1007 ± 327
Iron, mg 10.9 - 12.5 14.3 ± 5.6 13.9 ± 7.2
aValues are means ± SD, and did not differ between the groups (P > 0.05, Student’s t-test); bReference range for clinical chemistry parameters [31]; cReference
values for dietary intake (RDA) in Germany, Austria, Switzerland [32], ranges presented here apply to physical active people; VO2max maximum oxygen uptake,
Pmax maximum performance;




















Fig. 2 Stool concentrations of zonulin in trained subjects before and after 12 weeks of treatment. Values are means ± SD, P < 0.05 (ANOVA),
n = 27 (zeolite supplementation), n = 25 (Placebo)
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increased intestinal permeability [20]. The “leak” in the
paracellular absorption route enables antigens to pass
from the intestinal milieu, challenging the immune sys-
tem to produce an immune response and subsequent in-
flammation and oxidative stress [19, 21, 22]. Beside liver
cells, intestinal cells can synthesize zonulin and the
zonulin system can be activated by dietary proteins (es-
pecially gliadin) or enteric bacteria [20, 23].
Alpha1-antitrpysin is an acute phase protein synthesized
in liver cells. Its concentrations in feces serve as marker
for intestinal barrier integrity and is widely used to esti-
mate protein leakage into the intestinal tract [24, 25]. In
this study we observed significant reduced stool zonulin
concentrations after zeolite treatment but alpha1-
antitrypsin did not change after treatment and was
within reference range throughout the study. We are
convinced that, although our subjects showed indices
of a mild gut permeability disturbance at baseline
(zonulin slightly above cut-off ), this mild imbalance in
gut barrier function was not distinctive enough to pro-
voke an acute-phase response in liver cells via increased
alpha1-antitrypsin synthesis.
Nevertheless, the observed reduction of zonulin in the
zeolite supplemented group is remarkable as mean con-
centrations dropped from above cut-off into reference
range (<55 ng . mL-1). These data indicate that our
trained cohort suffered already a mild increase in intes-
tinal permeability at baseline, probably due to chronic
exercise training. Obviously the 12 weeks of zeolite sup-
plementation could reduce zonulin synthesis and hence
improve intestinal barrier integrity. Therefore we suggest
that the zeolite modulated the zonulin system, perhaps
by interacting with intestinal bacteria.
However, we have to admit that the mechanisms how
zeolite affects intestinal barrier are unclear. We believe
that one or more of the described zeolite properties
exerted in the intestinal tract like immunostimulation,
impact on inflammation, adsorbent or detergent proper-
ties, might have contributed to this result.
Redox markers
CP and GPx3 showed a significant influence of time with
higher values in both groups at the end of the study. Ba-
sically, higher concentrations in CP in trained cohorts
Table 2 Summary of results*; gut barrier integrity markers, oxidation markers, inflammatory markers
Variable Ptreat Ptime Zeolite Placebo Zeolite Placebo Reference
range0 week 0 week 12 weeks 12 weeks
zonulin 0.006 >0.1 61.2 ± 11.0 56.1 ± 13.2 43.8 ± 14.3 59.6 ± 12.3 <55
ng . mL-1
α1-antitrypsin >0.1 >0.1 27.6 ± 14.8 32.8 ± 15.6 30.2 ± 18.1 35.8 ± 17.7 <37.5
mg . dL-1
CP >0.1 <0.001 218 ± 102 206 ± 98 508 ± 108 486 ± 87 80–200
pmol . mg-1
iPF2α-III >0.1 >0.1 216 ± 55 200 ± 55 199 ± 73 181 ± 43 50–400
pg . mL-1
GPx3 >0.1 <0.001 131 ± 69 107 ± 58 182 ± 64 193 ± 59 33–98
IU . L-1
DNA SB >0.1 >0.1 0.36 ± 0.25 0.35 ± 0.24 0.49 ± 0.33 0.48 ± 0.29 0–70
AU
TNF-α >0.1 0.024 26.1 ± 8.7 24.3 ± 12.3 31.8 ± 11.5 28.7 ± 11.8 0–69
pg . mL-1
IL-6 >0.1 >0.1 26.6 ± 2.0 27.1 ± 1.7 27.7 ± 3.2 26.9 ± 2.7 <100
pg . mL-1
IL-8 >0.1 >0.1 38.1 ± 10.8 41.9 ± 12.0 39.7 ± 11.5 39.8 ± 9.7 0–62
pg . mL-1
IL-10 0.087 >0.1 40.1 ± 19.2 42.1 ± 16.0 54.5 ± 27.8 37.9 ± 22.2 none
pg . mL-1
IL-22 >0.1 >0.1 42.9 ± 4.2 41.4 ± 3.3 40.5 ± 3.3 40.1 ± 4.4 none
pg . mL-1
*Values are means ± SD; P < 0.05, ANOVA; n = 27 (Zeolite), n = 25 (Placebo); α1-antitrypsin alpha1-antitrypsin, CP carbonyl groups bounded on protein, iPF2α-III
isoprostanes F2α-III, GPx3 plasma glutathione peroxidase, DNA SB DNA strand-breaks, TNF-α tumor necrose factor alpha, IL interleukin, treat treatment
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and in relation to exercise are not new for us and we ob-
served and discussed this recently [26, 27]. But in this
study subjects were instructed to avoid changes in their
training regimens and lifestyles throughout the treat-
ment period and thus we cannot relate the increase of
these markers to a change in subject’s exercise training
regimens or stress profile. We suppose rather a mild nu-
tritional influence. The baseline values were collected in
fall and the study end was between January and March.
Although subjects were asked to avoid changes in food
intake, seasonal changes could lead to decreased micro-
nutrient and antioxidant intake over winter time which
in turn could have led to decreased protection of pro-
teins from oxidation and internal up-regulation of GPx3
activity to compensate redox state in plasma. Insofar this
is a realistic hypothesis as we know that a treatment
with higher concentrations of isolated antioxidants can
decrease plasma GPx3 activities within 3 weeks [28]. On
the contrary, interview data revealed that the subjects
adhered to the instruction to replicate their nutrition the
last days before visiting the study site for the second
time. Also vitamin C and uric acid, the main determi-
nants of plasma redox status, were unchanged after
12 weeks. However, this does not exclude dietary
changes in the intake of other, especially redox-active,
nutrients over the winter months.
Regarding the question whether a 1.85 g zeolite sup-
plementation could affect redox markers in healthy
trained subjects, we have to falsify this hypothesis. None
of the measured redox markers CP, GPx, 8-iso-PGF2α,
vitamin C and uric acid did react to the applied zeolite
treatment. Also DNA strand-breaks in peripheral mono-
nuclear cells did not show any changes. Obviously the
mild zeolite modulations in the intestinal wall did not
affect systemic redox markers in the blood.
Markers of inflammation
TNF-alpha, a marker of low-grade inflammation, was
not different between groups but increased towards the
end of the study in both groups. This is similar to CP
and GPx3 and we already observed a correlation be-
tween CP and TNF-alpha in the past [29], but related
this to common cold pathophysiology. We do not have
an explanation for this increase other than this change
might also be related to a reduced intake of food high in
micronutrients and antioxidants over winter time.
Nevertheless, although TNF-alpha concentrations in-
creased, all values observed were within the reference
range and thus, we think that the changes might be due
to biological variability.
The lack of inflammatory response to the treatment is
in line with the unobtrusive concentrations of the
inflammatory cytokines IL-6, IL-8, and IL-22, with no
differences between groups. In contrast the anti-
inflammatory IL-10 showed an increase by a trend in the
zeolite supplemented group compared to placebo. This
could reflect an anti-inflammatory modulation which
could be linked to the reduced intestinal wall permeabil-
ity in the zeolite group as indicated by significant zonu-
lin decrease after 12 weeks.
Performance data
In recent years more and more athletes from the field
reported to us about ergogenic effects after intake of
zeolite. Despite the lack of a comprehensible biological
rationale for this serious obeservations we decided to
evaluate the effects of zeolite supplementation on
VO2max and/or Pmax via exhaustive step wise incremen-
tal ergometry. With this double-blinded, placebo-
controlled study design and the model of standardized
performance testing applied in this trial, we could not
detect differences in VO2max and/or Pmax after 12 weeks
of supplementation. However, based on our results we
cannot generally exclude ergogenic effects of zeolite.
Perhaps another model of performance testing or the
same experiment conducted with another cohort, e.g.
with sedentary subjects, could reveal different results.
Further, the application of a higher dose than used in
our trial should be investigated. Our subjects received ~
1.85 g zeolite per day (6 capsules), which corresponds to
the lowest range of the vendor’s daily recommended
dose: it ranges from 1.85 g to 2.7 g per day, correspond-
ing to 6 – 9 capsules for healthy and recreationally ac-
tive individuals in order to promote health and
performance. Thus, additional research is needed to as-
certain under which conditions zeolite might be ergo-
genic or not.
Other blood parameters
As zeolites also contain aluminum [8, 11] we measured
serum AI, liver and kidney parameters at the beginning
and the end of the study to identify possible toxic effects.
We did not observe any changes in AI, AST, ALT, GGT,
or creatinine concentrations. The zeolite-clinoptilolite
supplement we used in this study had a low AI content,
according to the available (cyto-)toxicity certificates this
was 11 %, which does obviously not affect serum AI
concentrations or key hepatic markers when ingested
over 3 months. This also indicates that the AI absorp-
tion from this product was not of pathophysiological
relevance.
Limitations of the study
First, we did not conduct food recording towards the
end of the study to assess nutrient intake for a second
time. Another dietary analysis at the end of the treat-
ment period could have revealed some evidence whether
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our hypothesis of reduced micronutrient and antioxidant
intake over winter time could have substance or not.
Second, the number of valid biomarkers we used to es-
timate intestinal barrier integrity was limited. For future
studies, also other biomarkers such as lipopolysaccha-
rides or the lactulose-mannitol/rhamnose intestinal per-
meability test could be used.
Third, the determination of an enteric bacteria profile
and a microbiome analysis would be useful to correlate
such analyses to changes in our outcome measures.
Conclusions
Zeolite supplementation can beneficially affect intes-
tinal barrier integrity, accompanied by mild anti-
inflammatory effects in subjects undergoing regular
aerobic exercise training. Redox markers in blood,
VO2max and Pmax of trained subjects are not affected
by ~1.85 g zeolite supplementation over 3 months and
the applied model of performance testing. However,
our observations could be of practical relevance for
athletes under the perspective that an improved intestinal
barrier reduces athlete’s susceptibility to endotoxemia
[30]. Further research is needed to explore mechanistic
explanations for the observations in this study.
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